Navigation Links
Sirion Therapeutics Announces FDA Approval of Durezol(TM) for Treatment of Postoperative Ocular Inflammation and Pain
Date:6/24/2008

Durezol is First Ophthalmic Steroid Indicated for Inflammation and Pain

TAMPA, Fla., June 24 /PRNewswire/ -- Sirion Therapeutics, Inc., a privately held ophthalmic-focused biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has approved its new drug application for Durezol(TM) (difluprednate ophthalmic emulsion) 0.05%, a topical steroid for the treatment of postoperative ocular inflammation and pain. The approval came after a six month priority review.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080220/CLW064LOGO )

"Durezol, our first product to be approved by the FDA, is a potent topical steroid that works rapidly and effectively to resolve postoperative inflammation and pain," said Barry Butler, President and CEO of Sirion Therapeutics, Inc. "We look forward to launching the first innovation in the strong steroid class in more than 35 years, and the first steroid to have an indication for the treatment of postoperative pain. We believe that having access to a steroid that treats both inflammation and pain gives physicians a more complete treatment approach."

In two Phase 3 trials evaluating Durezol in patients diagnosed with significant postoperative inflammation (more than 10 anterior chamber cells), Durezol rapidly reduced inflammation and pain. Mean intraocular pressure (IOP) for all study groups remained within the normal range throughout the study.

"Rapid resolution of inflammation and pain is very important following ocular surgery," said Dr. Michael Korenfeld, M.D., Assistant Clinical Professor of Ophthalmology and Visual Sciences, Washington University, St. Louis, MO, and principal investigator for the Phase 3 trials. "It is important to point out that in these Phase 3 studies, patients were dosed for the first time after the ocular trauma from surgery had occurred. The results from these studi
'/>"/>

SOURCE Sirion Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Sirion Therapeutics Supports Ophthalmic Education
2. Sirion Therapeutics Acquires Worldwide License to Develop New Treatment for Ocular Diseases
3. Sirion Therapeutics Highlights Pivotal Trial Results of Durezol(TM) at the American Society of Cataract and Refractive Surgery Annual Symposium
4. Sirion Therapeutics Preclinical Studies: Two New Potential Advances in Treatment of Retinal Diseases to be Presented at ARVO
5. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
6. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
7. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
8. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
9. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
10. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
11. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... SAN DIEGO , Sept. 19, 2014 ... engaged in the development of high-value and difficult to ... will be presenting at the 21 st Annual ... New York . Bertrand Liang , chief ... the company,s development programs and business strategy on Friday, ...
(Date:9/19/2014)... 19, 2014 ... ) has announced the addition of the  "Micro ... to their offering.       (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... of the fastest-growing segments in the chromatography market. ... 2013, and expected to reach $2.0 billion by ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 ... urological and interventional radiology products and services, announced ... as cryotherapy and cryoablation) versus external beam radiotherapy ... of the American Urological Association (MAAUA) Annual Meeting ... "Comparing Relative Effectiveness of Cryosurgery and External Beam ...
(Date:9/18/2014)... Sept. 18, 2014  Health Enhancement Products, Inc. (OTCQB: HEPI), ... algae bioactive compounds and metabolic processes, is pleased to announce ... of directors. Ms. Nola E. Masterson , a ... the board effective September 17, 2014. "We,re ... join our board," states Andrew Dahl , President and ...
Breaking Biology Technology:Pfenex to Present at Upcoming Industry Conference on September 26 2Micro Market Monitor : Global Pre-packed Chromatography Columns 2HealthTronics Announces Data Comparing Cryotherapy Versus Radiation for Treating Prostate Cancer Poster Presented at the American Urological Association Regional Meeting 2Health Enhancement Announces New Board Member In Advance Of Annual Shareholder Meeting 2
... SOMERSET, N.J., June 9 Alfacell Corporation,(Nasdaq: ACEL ... quarter,of fiscal 2008., The company recorded a net ... diluted common share, for the third fiscal quarter ended,April ... million, or $0.04,per basic and diluted common share, for ...
... Limited (LSE: SHP,Nasdaq: SHPGY), the global specialty biopharmaceutical ... lots of the ADHD patch DAYTRANA (lots,2750211 and ... DAYTRANA,patches do not meet their release liner removal ... have difficulties removing the,liners. This voluntary recall is ...
... 9 Amira Pharmaceuticals, a small,molecule pharmaceutical company ... treat inflammatory diseases, announced the hiring of Michael,V. ... Swanson has over 30 years of experience in ... in life sciences and specialty,pharmaceutical companies. Prior to ...
Cached Biology Technology:Alfacell Reports Financial Results for Third Quarter of Fiscal 2008 2Alfacell Reports Financial Results for Third Quarter of Fiscal 2008 3Alfacell Reports Financial Results for Third Quarter of Fiscal 2008 4Alfacell Reports Financial Results for Third Quarter of Fiscal 2008 5Alfacell Reports Financial Results for Third Quarter of Fiscal 2008 6Non-Safety-Related Voluntary Recall of a Limited Portion of DAYTRANA(TM) (Methylphenidate Transdermal System) Patches Announced 2Non-Safety-Related Voluntary Recall of a Limited Portion of DAYTRANA(TM) (Methylphenidate Transdermal System) Patches Announced 3Non-Safety-Related Voluntary Recall of a Limited Portion of DAYTRANA(TM) (Methylphenidate Transdermal System) Patches Announced 4Amira Pharmaceuticals Hires Industry Veteran for CFO Position 2
(Date:9/18/2014)... have developed a unique method to use microbes buried ... areas. , The first microbe-powered, self-sustaining wastewater treatment ... to clean up waste from large farming operations and ... Professor Haluk Beyenal and graduate student Timothy Ewing in ... system in the online edition of Journal of ...
(Date:9/18/2014)... that can operate inside the bore of an MRI ... biomedical research partnership program at Brigham and Women,s Hospital ... robot, in conjunction with real-time MRI images, can make ... less discomforting for the patient. The novel system also ... greater precision. , Developed by a team of robotics ...
(Date:9/18/2014)... acquire and creatively manipulate spoken language is unique to ... 6 million years of human evolution to make this ... candidate gene we now have," says Wolfgang Enard, Professor ... efforts to understand the molecular biological basis of language ... results of his latest study, undertaken in collaboration with ...
Breaking Biology News(10 mins):Researchers develop unique waste cleanup for rural areas 2Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 2Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 3Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 4Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 5Language evolution: Quicker on the uptake 2Language evolution: Quicker on the uptake 3
... University is proving its potential to impact global health. ... journal PLoS ONE , Rice alumnus Andrew Miller ... which costs $240, stacks up nicely against devices that ... of tuberculosis. Miller and colleagues at The Methodist ...
... not recognized as an animal until the 19th century, is ... have their genome sequenced. In a paper appearing in ... a team of researchers led by Daniel Rokhsar of the ... Genome Institute (JGI), report the draft genome sequence of the ...
... How well do you understand life in your own backyard? Cities ... aren,t visitors; they are an integral component, like trees in a ... the Earth,s people live in cities and the amount of paved ... Ohio, shouldn,t our sciences thrive in the city? Urban Ecosystem ...
Cached Biology News:Compact microscope a marvel 2Compact microscope a marvel 3Genome of ancient sponge reveals origins of first animals, cancer 2Genome of ancient sponge reveals origins of first animals, cancer 3Genome of ancient sponge reveals origins of first animals, cancer 4The real urban jungle 2
... system is used for single-color real-time detection ... or JOE fluorophores and features a real-time ... data from 96 wells, a gene expression ... analysis. The system includes the optical module ...
... Precision-designed for Optimal Microdissection , CapSure HS ... precise and rapid extraction of populations of ... samples with Laser Capture Microdissection., Ensure ... Molecular Analysis , All CapSure LCM Caps ...
Opticon continuous fluorescence detector; includes optical base, analysis software, computer and monitor (this is an accessory for the DNA Engine thermal cyclers which must be ordered seperately)...
... systems are highly sensitive laser confocal systems ... are advanced scanners that meet your expectations, ... level, and optimizing the signal on the ... of the range for increased sensitivity. Results ...
Biology Products: